Autel to Present Full-Range Charging Innovations at Power2Drive Europe 2025
7.5.2025 09:03:00 CEST | Business Wire | Press Release
Autel, a global provider of EV charging technology, will showcase a comprehensive lineup of DC and AC charging systems at Power2Drive Europe, held from May 7–9 at Messe München. At Booth B6.350, the company will feature its latest high-performance solutions, including the MaxiCharger MCS Dispenser II and the MaxiCharger DH480, along with the MaxiCharger Single Charger, which was honored with the Red Dot 2025 Design Award. These technologies represent Autel’s ongoing efforts to contribute practical, future-oriented infrastructure solutions that align with the evolving needs of Europe’s e-mobility ecosystem.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507393060/en/
Autel Europe Full Range of EV Charging Solutions
Flexible EV Charging for Commercial and Public Applications
The MaxiCharger DH480 delivers up to 480kW across four simultaneous outputs, enabling efficient charging for multiple vehicles at once. Already deployed by several customers across Europe, it features a modular, all-in-one design that supports flexible installation and easy maintenance. These characteristics make it well-suited for a variety of settings, including fleet depots, urban charging hubs, and transport corridors.
The MaxiCharger MCS Dispenser II is designed for megawatt-level charging, offering a dual-output configuration that accommodates both MCS-enabled heavy-duty vehicles and standard CCS-based electric vehicles. This versatility makes it particularly useful for mixed-fleet operations preparing for zero-emission transport. With enhancements in cable management, thermal control, and load handling, the system is engineered for high-frequency use in demanding environments, helping reduce charging times and improve overall efficiency.
“At Autel, we aim to deliver charging solutions that combine high performance with practical usability,” said Andreas Lastei, Vice President of Sales and Marketing at Autel Energy Europe. “We continue to explore how our technologies can offer reliability, scalability, and adaptability in real-world scenarios. Power2Drive is an important event to engage with the industry and share how we're approaching the challenges and opportunities of Europe’s e-mobility transition.”
Red Dot 2025 Design Award for MaxiCharger Single Charger
Autel will also showcase the MaxiCharger Single Charger, winner of the Red Dot 2025 Design Award. Built for public, commercial, and residential applications, it offers fast installation with one-click snap-in setup, 10-minute site-wide commissioning, and ISO15118 compliance for Plug & Charge and AutoCharge. The charger also supports multiple payment methods and is ready for integration with PV and energy storage systems.
Visit Autel at Booth B6.350
Autel welcomes attendees of Power2Drive Europe 2025 to discover its portfolio of EV charging solutions—from high-capacity commercial systems to award-winning residential chargers. Focused on reliability, flexibility, and intelligent design, Autel supports Europe’s transition to electric mobility.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250507393060/en/
Contacts
jiaqi.liu@autel.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom